Issues of biochemical applications to risk assessment: how should the MTD be selected for chronic bioassays?

. 1987 Dec;76:169–174. doi: 10.1289/ehp.8776169

PMCID: PMC1474474 PMID: 3447894

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Haseman J. K. Issues in carcinogenicity testing: dose selection. Fundam Appl Toxicol. 1985 Feb;5(1):66–78. doi: 10.1016/0272-0590(85)90050-8. [DOI] [PubMed] [Google Scholar]
Meyers D. B., Young S. S., Gries C. L. Design of cancer assays for pharmaceutical agents. J Natl Cancer Inst. 1985 May;74(5):1151–1152. [PubMed] [Google Scholar]
Young S. S., Brannon D. R. Dose selection for long-term rodent carcinogenicity studies. Fundam Appl Toxicol. 1986 Jan;6(1):185–188. doi: 10.1016/0272-0590(86)90277-0. [DOI] [PubMed] [Google Scholar]